74 related articles for article (PubMed ID: 25057941)
21. Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer.
Stabile LP; Lyker JS; Land SR; Dacic S; Zamboni BA; Siegfried JM
Carcinogenesis; 2006 Aug; 27(8):1547-55. PubMed ID: 16513678
[TBL] [Abstract][Full Text] [Related]
22. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
[No Abstract] [Full Text] [Related]
23. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.
Stabile LP; Rothstein ME; Keohavong P; Jin J; Yin J; Land SR; Dacic S; Luong TM; Kim KJ; Dulak AM; Siegfried JM
Mol Cancer Ther; 2008 Jul; 7(7):1913-22. PubMed ID: 18645002
[TBL] [Abstract][Full Text] [Related]
24. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
[TBL] [Abstract][Full Text] [Related]
25. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
Saba NF; Hurwitz SJ; Kono SA; Yang CS; Zhao Y; Chen Z; Sica G; Müller S; Moreno-Williams R; Lewis M; Grist W; Chen AY; Moore CE; Owonikoko TK; Ramalingam S; Beitler JJ; Nannapaneni S; Shin HJ; Grandis JR; Khuri FR; Chen ZG; Shin DM
Cancer Prev Res (Phila); 2014 Mar; 7(3):283-91. PubMed ID: 24085777
[TBL] [Abstract][Full Text] [Related]
26. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.
Siebzehnrubl FA; Silver DJ; Tugertimur B; Deleyrolle LP; Siebzehnrubl D; Sarkisian MR; Devers KG; Yachnis AT; Kupper MD; Neal D; Nabilsi NH; Kladde MP; Suslov O; Brabletz S; Brabletz T; Reynolds BA; Steindler DA
EMBO Mol Med; 2013 Aug; 5(8):1196-212. PubMed ID: 23818228
[TBL] [Abstract][Full Text] [Related]
27. Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4.
Lin X; Shang X; Manorek G; Howell SB
PLoS One; 2013; 8(6):e67496. PubMed ID: 23805314
[TBL] [Abstract][Full Text] [Related]
28. Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy.
Fu S; Rivera M; Ko EC; Sikora AG; Chen CT; Vu HL; Cannan D; Eisenstein S; Rosenstein BS; Aguirre-Ghiso J; Chen SH; Kao J
J Cell Sci Ther; 2011 Oct; 1(2):. PubMed ID: 23483082
[TBL] [Abstract][Full Text] [Related]
29. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Shin DM; Zhang H; Saba NF; Chen AY; Nannapaneni S; Amin AR; Müller S; Lewis M; Sica G; Kono S; Brandes JC; Grist WJ; Moreno-Williams R; Beitler JJ; Thomas SM; Chen Z; Shin HJ; Grandis JR; Khuri FR; Chen ZG
Clin Cancer Res; 2013 Mar; 19(5):1244-56. PubMed ID: 23422093
[TBL] [Abstract][Full Text] [Related]
30. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
[TBL] [Abstract][Full Text] [Related]
31. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer.
Ujiie H; Tomida M; Akiyama H; Nakajima Y; Okada D; Yoshino N; Takiguchi Y; Tanzawa H
Anticancer Res; 2012 Aug; 32(8):3251-8. PubMed ID: 22843899
[TBL] [Abstract][Full Text] [Related]
32. Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.
Okada T; Takigawa N; Kishino D; Katayama H; Kuyama S; Sato K; Mimoto J; Ueoka H; Tanimoto M; Kiura K
Acta Med Okayama; 2012; 66(3):245-51. PubMed ID: 22729105
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
[TBL] [Abstract][Full Text] [Related]
35. Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
Surati M; Patel P; Peterson A; Salgia R
Expert Opin Biol Ther; 2011 Dec; 11(12):1655-62. PubMed ID: 22047509
[TBL] [Abstract][Full Text] [Related]
36. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.
Ogunwobi OO; Liu C
Clin Exp Metastasis; 2011 Dec; 28(8):721-31. PubMed ID: 21744257
[TBL] [Abstract][Full Text] [Related]
37. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer.
Pine SR; Mechanic LE; Enewold L; Chaturvedi AK; Katki HA; Zheng YL; Bowman ED; Engels EA; Caporaso NE; Harris CC
J Natl Cancer Inst; 2011 Jul; 103(14):1112-22. PubMed ID: 21685357
[TBL] [Abstract][Full Text] [Related]
38. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Ou SH; Kwak EL; Siwak-Tapp C; Dy J; Bergethon K; Clark JW; Camidge DR; Solomon BJ; Maki RG; Bang YJ; Kim DW; Christensen J; Tan W; Wilner KD; Salgia R; Iafrate AJ
J Thorac Oncol; 2011 May; 6(5):942-6. PubMed ID: 21623265
[TBL] [Abstract][Full Text] [Related]
39. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression.
Wang R; Zhang J; Chen S; Lu M; Luo X; Yao S; Liu S; Qin Y; Chen H
Lung Cancer; 2011 Nov; 74(2):188-96. PubMed ID: 21601305
[TBL] [Abstract][Full Text] [Related]
40. HGF-independent potentiation of EGFR action by c-Met.
Dulak AM; Gubish CT; Stabile LP; Henry C; Siegfried JM
Oncogene; 2011 Aug; 30(33):3625-35. PubMed ID: 21423210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
